ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 16

Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups

Hanna Kim1, Angélique Biancotto2, Foo Cheung3, Terrance P. O'Hanlon4, Ira N. Targoff5, Yan Huang6, Frederick Miller4, Raphaela Goldbach-Mansky6 and Lisa G. Rider4, 1Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, 2Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 3Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 4Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 5VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: autoantibodies, Biomarkers, juvenile dermatomyositis, pathogenesis and proteomics

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, May 18, 2017

Session Title: Genetics and Pathogenesis Poster Breakout I

Session Type: Abstract Submissions

Session Time: 4:45PM-5:15PM

Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease.  Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes within JDM and may indicate distinct pathogeneses.  To define biomarkers and better understand JDM pathogenesis, aptamer-based proteomic technology was used to mine the serum proteome in a well-characterized JDM cohort.

Methods:   Sera from 41 JDM patients (prevalent cases on variable treatment) selected for higher disease activity (physician global activity or PGA median 4.0 (IQR 3.0-5.0)) with anti-p155/140 or TIF1 (n=21), NXP2 (n=10), and MDA5 (n=10) MSAs, were compared with 28 age- and gender-matched healthy controls (HC). Broad proteomic analysis of 1306 targets using SOMAscan assay of slow off-rate modified aptamers (SomaLogic, CO) generated simultaneous quantitative serum levels. Individual MSA group vs. HC proteins with Mann-Whitney FDR-corrected p values of <0.05 with expression ratio of >1.3 were analyzed using Ingenuity Pathway Analysis or IPA (Qiagen, CA). 

Results: 62, 41, and 67 proteins, met above criteria with overexpression (>1.3 ratio versus HC) with 13, 4, and 13 proteins specific to TIF1, NXP2, and MDA5 MSA groups respectively and 26 shared in all 3 groups and 31 shared in 2 groups (Figure 1). Top 10 proteins by MSA group are listed in Table 1. Within the top 20 dysregulated pathways by MSA group by IPA, Th1 and Th2 activation, acute phase response, IFN, and glucocorticoid receptor signaling were shared to all 3 MSA groups.  Further analysis by MSA group is ongoing.

Conclusion: Preliminary broad quantitative proteomic analysis by MSA group compared to HC identified Th1/ Th2, acute phase response, IFN, and glucocorticosteroid receptor signaling shared in all MSA groups. Unique protiens were identified by MSA group, but further analysis by MSA group is pending. While in need of confirmation in other cohorts, these proteins identified through a high-throughput screen bring to light new pathways that may be important in JDM and potential MSA-group specific pathogenesis.

This research was supported by the Cure JM Foundation and the Intramural Research Program of the NIH, NIAMS, NIEHS, NHLBI, NIAID, and the CC. 


Disclosure: H. Kim, 2; A. Biancotto, None; F. Cheung, None; T. P. O'Hanlon, None; I. N. Targoff, 6; Y. Huang, None; F. Miller, None; R. Goldbach-Mansky, None; L. G. Rider, 2.

To cite this abstract in AMA style:

Kim H, Biancotto A, Cheung F, O'Hanlon TP, Targoff IN, Huang Y, Miller F, Goldbach-Mansky R, Rider LG. Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/novel-serum-broad-based-proteomic-discovery-analysis-identifies-proteins-and-pathways-dysregulated-in-juvenile-dermatomyositis-jdm-myositis-autoantibody-groups/. Accessed March 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-serum-broad-based-proteomic-discovery-analysis-identifies-proteins-and-pathways-dysregulated-in-juvenile-dermatomyositis-jdm-myositis-autoantibody-groups/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences